NSC 326408
Rocaglamide
CAS: 84573-16-0
Molecular Formula: C29H31NO7
NSC 326408 - Names and Identifiers
NSC 326408 - Physico-chemical Properties
| Molecular Formula | C29H31NO7 |
| Molar Mass | 505.56 |
| Density | 1.321±0.06 g/cm3(Predicted) |
| Melting Point | 117-118 °C |
| Boling Point | 667.3±55.0 °C(Predicted) |
| Solubility | Soluble in DMSO or Ethanol |
| Appearance | Powder |
| Color | colorless |
| pKa | 11.70±0.70(Predicted) |
| Storage Condition | -20°C |
| Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month. Protect from exposure to light and moisture. |
| In vitro study | Rocaglamide enhances TRAIL-induced apoptosis in resistant HCC cells. Treatment with Rocaglamide alone leads to apoptosis in 9% HepG2 and 11% Huh-7 cells and treatment with TRAIL induces apoptosis in 16% HepG2 and 17% Huh-7 cells. However, the combination of Rocaglamide and TRAIL induces apoptosis in 55% HepG2 and 57% Huh-7 cells, which is evidently more than an additive effect. A similar result is obtained by measurement of cell viability using crystal violet staining. Rocaglamide has the potential to sensitize highly chemoresistant HepG2 and Huh-7 cells to TRAIL-based therapy. |
| In vivo study | Tumor volumes in the Rocaglamide-treated group are 45±12% compared with the control group. Rocaglamide significantly suppresses tumor growth compared with that in the control group. Treatment with Rocaglamide does not lead to any reduction in body weight and no apparent signs of toxicity are observed in the mice during the treatment, suggesting that Rocaglamide is generally tolerated well. |
NSC 326408 - Risk and Safety
| WGK Germany | 3 |
NSC 326408 - Reference Information
| biological activity | Rocaglamide (Roc-A) is isolated from Aglaia and can be used for cough, injury, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T cells. Rocaglamide is a potent selective heat shock factor 1 (HSF1) activation inhibitor with an IC50 of about 50 nM. Rocaglamide also inhibit the function of translation initiation factor eIF4A. Rocaglamide also has anti-cancer properties. |
| target | HSF1 50 nM (IC 50 ) |
| in vitro study | Rocaglamide enhances TRAIL-induced apoptosis in resistant HCC cells. Treatment with Rocaglamide alone led to apoptosis in 9% HepG2 and 11% Huh-7 cells and treatment with TRAIL induces apoptosis in 16% HepG2 and 17% Huh-7 cells. However, the combination of Rocaglamide and TRAIL induces apoptosis in 55% HepG2 and 57% Huh-7 cells, which is evidently more than an additive effect. A similar result is obtained by measurement of cell viability using crystal violet staining. Rocaglamide has the potential to sensitize high chemoresistant HepG2 and Huh-7 cells to TRAIL-based therapy. |
| in vivo research | Tumor volumes in the Rocaglamide-treated group are 45±12% compared with the control group. Rocaglamide significantly suppresses tumor growth compared with that in the control group. Treatment with Rocaglamide does not lead to any reduction in body weight and no apparent signs of toxicity are observed in the treatment, suggesting that Rocaglamide is generally tolerated well. |
Last Update：2024-04-09 21:21:28
Supplier List
Product Name: Rocaglamide Visit Supplier Webpage Request for quotation
CAS: 84573-16-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 84573-16-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: Rocaglamide Visit Supplier Webpage Request for quotation
CAS: 84573-16-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 84573-16-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History